IP Library Granted Patent US 12,473,578
Granted Patent B2
US 12,473,578 · App. 17/778,712 · Granted Nov 18, 2025

Carbonyl reductase, nucleic acid encoding same, and method for producing optically active compound using same

Inventors: Takanobu Iura (Tokyo, JP); Yasumasa Dekishima (Tokyo, JP); Takeshi Sakamoto (Tokyo, JP); Mari Hara (Tokyo, JP); Hirotoshi Hiraoka (Osaka, JP); Harald Gröger (Bielefeld, DE); Jieun Choi (Berlin, DE)
Assignee: UBE CORPORATION
C12P17/167C12N9/0006C12Y101/01184
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,473,578
App. No.
17/778,712
Granted
Nov 18, 2025
Kind
B2
Abstract

The present invention provides a carbonyl reductase having the activity of reducing a carbonyl group-containing compound to convert the compound into an optically active compound, and a production method of an optically active compound using the enzyme. Specifically, a carbonyl reductase having one or more mutations in which the 54th aspartic acid, the 157th methionine, the 170th alanine, the 211th isoleucine, the 214th methionine, and the 249th methionine are each substituted by other specific amino acid in the amino acid sequence shown in SEQ ID NO: 1 or a homologue of the amino acid sequence, and a production method of an optically active compound using the same are provided.

Claims (45)

1 . A carbonyl reductase variant comprising an amino acid sequence having at least 90% and less than 100% sequence identity to SEQ ID NO:1 and having carbonyl reductase activity, the variant comprising at least one or more mutation selected from the group of mutations consisting of:

(a) a mutation in which the 54th aspartic acid in SEQ ID NO: 1 is substituted by valine;

(b) a mutation in which the 157th methionine in SEQ ID NO: 1 is substituted by valine;

(c) a mutation in which the 170th alanine in SEQ ID NO: 1 is substituted by serine;

(d) a mutation in which the 211th isoleucine in SEQ ID NO: 1 is substituted by alanine or asparagine;

(e) a mutation in which the 214th methionine in SEQ ID NO: 1 is substituted by leucine; and

(f) a mutation in which the 249th methionine in SEQ ID NO: 1 is substituted by leucine.

2 . The carbonyl reductase variant according to claim 1 , comprising at least two mutations selected from the group of mutations.

3 . The carbonyl reductase variant according to claim 1 , further comprising (g) a mutation in which the 166th valine in SEQ ID NO: 1 is substituted by alanine.

4 . A method for producing an optically active compound represented by the following formula (IV):

wherein:

R is a hydrogen atom, an alkyl group, or an aryl group, and

is a substituent having an aromatic ring or a heterocycle, the method comprising:

asymmetrically reducing a carbonyl group-containing compound selected from the group consisting of compounds represented by the following formulas (I), (II) and (III):

in the above-mentioned formulas (I), (II) and (III), R is as defined above, and

is as defined above, by bringing the carbonyl group-containing compound into contact with an enzyme, a microorganism or cell having the ability to produce the enzyme, a processed product of the microorganism or cell, or a culture medium containing the enzyme obtained by culturing the microorganism or cell:

wherein the enzyme is a carbonyl reductase variant comprising an amino acid sequence having at least 90% and less than 100% sequence identity to SEQ ID NO: 1 and having carbonyl reductase activity, the variant comprising at least one or more mutation selected from the group consisting of:

(a) a mutation in which the 54th aspartic acid in SEQ ID NO: 1 is substituted by valine;

(b) a mutation in which the 157th methionine in SEQ ID NO: 1 is substituted by valine;

(c) a mutation in which the 170th alanine in SEQ ID NO: 1 is substituted by serine;

(d) a mutation in which the 211th isoleucine in SEQ ID NO: 1 is substituted by alanine or asparagine;

(e) a mutation in which the 214th methionine in SEQ ID NO: 1 is substituted by leucine; and

(f) a mutation in which the 249th methionine in SEQ ID NO: 1 is substituted by leucine.

5 . The production method according to claim 4 , wherein the carbonyl group-containing compounds represented by the formula (II) and the formula (III) are respectively an optically active form represented by the following formula (II′):

and an optically active form represented by the following formula (III′):

wherein R and

are as defined above.

6 . The production method according to claim 4 , wherein the substituent

wherein

is a substituent having an aromatic ring or a heterocycle,

7 . The production method according to claim 6 , wherein the substituent

8 . The production method according to claim 4 , wherein the microorganism or cell is a microorganism or cell transformed with a nucleic acid encoding said carbonyl reductase variant and comprising a nucleotide sequence having not less than 90% and less than 100% sequence identity to SEQ ID NO: 2 and encoding a polypeptide having carbonyl reductase activity.

9 . A composition comprising:

an enzyme, wherein the enzyme is the carbonyl reductase variant according to claim 1 ,

a microorganism or cell having the ability to produce the enzyme,

a processed product of the microorganism or cell, or

a culture solution containing the enzyme obtained by:

culturing the microorganism or cell, and

catalyzing a reaction using a carbonyl group-containing compound represented by formula (I), (II), or (III):

to produce an optically active compound represented by formula (IV):

wherein in formulas (I), (II), (III), and (IV):

R is a hydrogen atom, an alkyl group, or an aryl group, and

is a substituent having an aromatic ring and/or a heterocycle.

10 . The method according to claim 4 , wherein the carbonyl reductase variant comprises at least two mutations selected from the group of mutations.

11 . The method according to claim 4 , wherein the carbonyl reductase variant further comprises (g) a mutation in which the 166th valine in SEQ ID NO: 1 is substituted by alanine.

Assignments (3)
MERGER Recorded Sep 10, 2025
From: API CORPORATION
To: UBE CORPORATION
Reel/Frame 072827/0104 →
CHANGE OF ADDRESS Recorded Jun 21, 2023
From: API CORPORATION
To: API CORPORATION
Reel/Frame 064103/0580 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 15, 2022
From: IURA, TAKANOBU; DEKISHIMA, YASUMASA; SAKAMOTO, TAKESHI; HARA, MARI; HIRAOKA, HIROTOSHI; GRÖGER, HARALD; CHOI, JIEUN
To: API CORPORATION
Reel/Frame 060513/0920 →
Priority Claims (1)
JP 2019-211797 · Nov 22, 2019 · national
Continuity (1)
Related Publication 20230025343A1 · Jan 26, 2023
References Cited (30)
US 7332312B2 · Kizaki · 2008 [cited by examiner]
US 7335757B2 · Hiraoka · 2008 [cited by examiner]
US 7794993B2 · Kizaki · 2010 [cited by examiner]
US 20050048633A1 · Hiraoka et al. · 2005 [cited by applicant]
US 20080261281A1 · Kizaki et al. · 2008 [cited by applicant]
US 20160347718A1 · Watanabe et al. · 2016 [cited by applicant]
US 20170152488A1 · Hong et al. · 2017 [cited by applicant]
US 20180222865A1 · Watanabe et al. · 2018 [cited by applicant]
EP 2562253A1 · 2013 [cited by applicant]
JP 2003339387A · 2003 [cited by applicant]
JP 4270918B2 · 2009 [cited by applicant]
JP 2017518744A · 2017 [cited by applicant]
WO WO2006013801A1 · 2006 [cited by applicant]
WO WO2011132444A1 · 2011 [cited by applicant]
WO WO2015119261A1 · 2015 [cited by applicant]
WO WO2017022846A1 · 2017 [cited by applicant]
Banerjee et al., Improving enzymes for biomass conversion: A basic research perspective. Bioenerg. Res., 2010, vol. 3: 82-92. (Year: 2010). [cited by examiner]
Broun et al., Catalytic plasticity of fatty acid modification enzymes underlying chemical diversity of plant lipids. Science, 1998, vol. 282: 1315-1317. (Year: 1998). [cited by examiner]
Chica et al., Semi-rational approaches to engineering enzyme activity: combining the benefits of directed evolution and rational design. Curr. Opi. Biotechnol., 2005, vol. 16: 378-384. (Year: 2005). [cited by examiner]
Devos et al., Practical limits of function prediction. Proteins: Structure, Function, and Genetics. 2000, vol. 41: 98-107. (Year: 2000). [cited by examiner]
Seffernick et al., Melamine deaminase and Atrazine chlorohydrolase: 98 percent identical but functionally different. J. Bacteriol., 2001, vol. 183 (8): 2405-2410. (Year: 2001). [cited by examiner]
Sen et al., Developments in directed evolution for enzyme functions. Appl. Biochem. Biotechnol., 2007, vol. 143: 212-223. (Year: 2007). [cited by examiner]
Whisstock et al., Prediction of protein function from protein sequence. Q. Rev. Biophysics., 2003, vol. 36 (3): 307-340. (Year: 2003). [cited by examiner]
Witkowski et al., Conversion of b-ketoacyl synthase to a Malonyl Decarboxylase by replacement of the active cysteine with glutamine. Biochemistry, 1999, vol. 38: 11643-11650. (Year: 1999). [cited by examiner]
ISR for PCT/JP2020/043366, dated Jan. 19, 2021. [cited by applicant]
Written Opinion for PCT/JP2020/043366, dated Jan. 19, 2021 (w/ translation). [cited by applicant]
Honda et al., “Improvement of operational stability of [cited by applicant]
Honda et al., “Expression of engineered carbonyl reductase from [cited by applicant]
EESR for EP App. No. 2088977.6, dated Dec. 6, 2023. [cited by applicant]
Office Action for JP App. No. 2021-558467, dated Nov. 12, 2024 (w/ translation). [cited by applicant]